Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

@article{Weber2017SafetyPO,
  title={Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.},
  author={Jeffrey S Weber and F Stephen Hodi and Jedd D Wolchok and Suzanne Louise Topalian and Dirk Schadendorf and James Larkin and Mario Sznol and Georgina V Long and Hewei Li and Ian M Waxman and Joel Jiang and Caroline Robert},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 7},
  pages={785-792}
}
  • Jeffrey S Weber, F Stephen Hodi, +9 authors Caroline Robert
  • Published 2017 in
    Journal of clinical oncology : official journal…
  • DOI:10.1200/JCO.2015.66.1389
Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. Patients and Methods Safety data were pooled from four studies, including two phase III trials, with patients who received nivolumab 3 mg/kg once every 2 weeks. We evaluated rate of treatment-related AEs, time to onset and resolution of select AEs (those with potential… CONTINUE READING
57 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…